{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:10:33Z","timestamp":1792181433177,"version":"4.4.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ekir.2025.07.020","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T15:59:29Z","timestamp":1753372769000},"page":"3340-3355","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Randomized Trial of Dapagliflozin in Patients With Nondiabetic Stage 4 CKD"],"prefix":"10.1016","volume":"10","author":[{"given":"Matias","family":"Trillini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Perna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobia","family":"Peracchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Fidone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Rubis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Guarinoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Martinetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Chiappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziano","family":"Gamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Perticucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Gambara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Rota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Stucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola","family":"Carrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Remuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Ruggenenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Remuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norberto","family":"Perico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matias","family":"Trillini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Daina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Bresin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Curt\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Gherardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Cugini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Prandini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veruscka","family":"Lecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Cad\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Gamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Diffideni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Guarinoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Gennarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosa","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Leone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Rota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Rubis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wally","family":"Calini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olimpia","family":"Diadei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Martinetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Carminati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Antonio","family":"Giuliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Perna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Peraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobia","family":"Peracchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Caroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Remuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Brambilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Abbadini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Sironi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Cugini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Gaspari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola","family":"Carrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Stucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Nicola","family":"Cannata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Boccardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Peracchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Piffari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Gregis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Borchetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Taddei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Diani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ekir.2025.07.020_bib1","first-page":"3","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"2013","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.ekir.2025.07.020_bib3","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1093\/ndt\/gfz174","article-title":"A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases","volume":"34","author":"Jager","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2025.07.020_bib4","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney disease and increased mortality risk in type 2 diabetes","volume":"24","author":"Afkarian","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.07.020_bib5","doi-asserted-by":"crossref","first-page":"414","DOI":"10.2471\/BLT.17.206441","article-title":"The global burden of kidney disease and the sustainable development goals","volume":"96","author":"Luyckx","year":"2018","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.ekir.2025.07.020_bib6","series-title":"Annual data report:Epidemiology of kidney disease in the United States","year":"2024"},{"key":"10.1016\/j.ekir.2025.07.020_bib7","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfae015","article-title":"The risk of CKD progression remains high in patients treated with ACE inhibitors and ARBs, MRAs and SGLT2 inhibitors. Have we already achieved the therapeutic ceiling in CKD? (The CON part)","volume":"17","author":"Trillini","year":"2024","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2025.07.020_bib8","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.07.020_bib9","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.07.020_bib10","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.07.020_bib11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2025.07.020_bib12","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.07.020_bib13","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.07.020_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101240","article-title":"Nephrotic-range proteinuria in type 2 diabetes: effects of empagliflozin on kidney disease progression and clinical outcomes","volume":"43","author":"Ruggenenti","year":"2022","journal-title":"EClinicalmedicine"},{"key":"10.1016\/j.ekir.2025.07.020_bib15","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.07.020_bib16","doi-asserted-by":"crossref","first-page":"700","DOI":"10.2215\/CJN.06080616","article-title":"SGLT2 Inhibition in the diabetic kidney-from mechanisms to clinical outcome","volume":"12","author":"van Bommel","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.07.020_bib17","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/clpt.2008.250","article-title":"Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus","volume":"85","author":"Komoroski","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ekir.2025.07.020_bib18","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.07.020_bib19","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","article-title":"Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Barnett","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2025.07.020_bib20","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1172\/JCI112013","article-title":"Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass","volume":"76","author":"Anderson","year":"1985","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ekir.2025.07.020_bib21","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1681\/ASN.2012040390","article-title":"Mechanisms and treatment of CKD","volume":"23","author":"Ruggenenti","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.07.020_bib22","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1172\/JCI27699","article-title":"Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes","volume":"116","author":"Remuzzi","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ekir.2025.07.020_bib23","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy","volume":"349","author":"Ruggenenti","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2025.07.020_bib24","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/S0140-6736(98)04433-X","article-title":"Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy","volume":"352","author":"Ruggenenti","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2025.07.020_bib25","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.07.020_bib26","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1161\/CIRCULATIONAHA.118.037418","article-title":"Evaluation of glomerular hemodynamic function by empagliflozin in diabetic mice using in vivo imaging","volume":"140","author":"Kidokoro","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2025.07.020_bib27","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2025.07.020_bib28","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1007\/s00125-014-3396-4","article-title":"Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration","volume":"57","author":"Skrti\u0107","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.ekir.2025.07.020_bib29","doi-asserted-by":"crossref","first-page":"F184","DOI":"10.1152\/ajprenal.00043.2017","article-title":"Urinary adenosine excretion in type 1 diabetes","volume":"313","author":"Rajasekeran","year":"2017","journal-title":"Am J Physiol Ren Physiol"},{"key":"10.1016\/j.ekir.2025.07.020_bib30","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.kint.2019.09.013","article-title":"The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial","volume":"97","author":"van Bommel","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.07.020_bib31","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1681\/ASN.V62257","article-title":"Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate","volume":"6","author":"Gaspari","year":"1995","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.07.020_bib32","first-page":"342","article-title":"Evaluation of a short protocol for the determination of para-aminohippurate and inulin plasma clearances","volume":"7","author":"Minetti","year":"1994","journal-title":"J Nephrol"},{"key":"10.1016\/j.ekir.2025.07.020_bib33","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1172\/JCI102534","article-title":"Evaluation of renal resistances, with special reference to changes in essential hypertension","volume":"30","author":"Gomez","year":"1951","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ekir.2025.07.020_bib34","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00592-021-01804-9","article-title":"Glomerular resistances predict long-term GFR decline in type 2 diabetic patients without overt nephropathy: a longitudinal subgroup analysis of the DEMAND trial","volume":"59","author":"Carrara","year":"2022","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.ekir.2025.07.020_bib35","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(98)10363-X","article-title":"Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria","volume":"354","author":"Ruggenenti","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2025.07.020_bib36","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S2213-8587(20)30162-5","article-title":"Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial","volume":"8","author":"Cherney","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2025.07.020_bib39","doi-asserted-by":"crossref","first-page":"693","DOI":"10.7326\/M23-1874","article-title":"Sodium\u2013glucose Cotransporter-2 inhibitors and the risk for dialysis and cardiovascular disease in patients with Stage 5 chronic kidney disease","volume":"177","author":"Yen","year":"2024","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ekir.2025.07.020_bib40","first-page":"F53","article-title":"Glomerular dysfunction induced by polymorphonuclear leukocyte-derived reactive oxygen species","volume":"257","author":"Yoshioka","year":"1989","journal-title":"Am J Physiol"},{"key":"10.1016\/j.ekir.2025.07.020_bib41","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/sj.ki.5002161","article-title":"Possible mechanism of efferent arteriole (Ef-Art) tubuloglomerular feedback","volume":"71","author":"Ren","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.07.020_bib42","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/sj.ki.5002199","article-title":"Tubuloglomerular feedback responses of the downstream efferent resistance: unmasking a role for adenosine?","volume":"71","author":"Blantz","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.07.020_bib43","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1152\/physrev.00031.2005","article-title":"Adenosine and kidney function","volume":"86","author":"Vallon","year":"2006","journal-title":"Physiol Rev"},{"key":"10.1016\/j.ekir.2025.07.020_bib44","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1681\/ASN.2022020207","article-title":"Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized crossover clinical trial","volume":"33","author":"Provenzano","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.07.020_bib45","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1172\/JCI112521","article-title":"Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension","volume":"77","author":"Zatz","year":"1986","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ekir.2025.07.020_bib46","first-page":"36","article-title":"Effect of low-dose enalapril on glomerular size-selectivity in human diabetic nephropathy","volume":"6","author":"Remuzzi","year":"1993","journal-title":"J Nephrol"},{"key":"10.1016\/j.ekir.2025.07.020_bib47","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1172\/JCI112528","article-title":"Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat","volume":"77","author":"Anderson","year":"1986","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ekir.2025.07.020_bib48","doi-asserted-by":"crossref","first-page":"76","DOI":"10.2337\/diacare.39.1.76","article-title":"Effects of converting-enzyme inhibition on barrier function in diabetic glomerulopathy","volume":"39","author":"Morelli","year":"1990","journal-title":"Diabetes"},{"key":"10.1016\/j.ekir.2025.07.020_bib49","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1681\/ASN.V4140","article-title":"Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes","volume":"4","author":"Remuzzi","year":"1993","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.07.020_bib50","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/ki.1991.160","article-title":"Angiotensin converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy","volume":"39","author":"Remuzzi","year":"1991","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.07.020_bib51","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1046\/j.1523-1755.2002.00535.x","article-title":"Effect of high dose ramipril with or without indomethacin on glomerular selectivity","volume":"62","author":"Pisoni","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.07.020_bib52","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/bmj.304.6823.339","article-title":"Renal protective effect of enalapril in diabetic nephropathy","volume":"304","author":"Bjorck","year":"1992","journal-title":"BMJ"},{"key":"10.1016\/j.ekir.2025.07.020_bib53","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1681\/ASN.2007090970","article-title":"Role of remission clinics in the longitudinal treatment of CKD","volume":"19","author":"Ruggenenti","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.07.020_bib54","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1146\/annurev-physiol-042022-031925","article-title":"Arterial stiffness: from basic primers to integrative physiology","volume":"86","author":"Regnault","year":"2024","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.ekir.2025.07.020_bib55","doi-asserted-by":"crossref","first-page":"220","DOI":"10.2337\/diacare.14.3.220","article-title":"Central role of sodium in hypertension in diabetic subjects","volume":"14","author":"Weidmann","year":"1991","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2025.07.020_bib56","doi-asserted-by":"crossref","first-page":"F1087","DOI":"10.1152\/ajprenal.00340.2016","article-title":"Insulin resistance in chronic kidney disease: a systematic review","volume":"311","author":"Spoto","year":"2016","journal-title":"Am J Physiol Ren Physiol"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024925004644?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024925004644?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:32:36Z","timestamp":1760002356000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024925004644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":53,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2468024925004644"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2025.07.020","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized Trial of Dapagliflozin in Patients With Nondiabetic Stage 4 CKD","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2025.07.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}